跳转至内容
Merck
CN

E-075

雌酚酮 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C18H22O2
化学文摘社编号:
53-16-7
分子量:
270.37
NACRES:
NA.24
PubChem Substance ID:
329798986
UNSPSC Code:
41116107
MDL number:
MFCD00003620

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

雌酚酮 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI

1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1

SMILES string

CC12CCC3C(CCc4cc(O)ccc34)C1CCC2=O

InChI key

DNXHEGUUPJUMQT-CBZIJGRNSA-N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing
clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

300

Gene Information

human ... ESR1(2099)

相关类别

General description

通过LC-MS/MS或GC/MS监测血清或血浆中雌二醇，雌酮的前体，以评估和诊断女性的发育异常，酶失活或缺乏，多囊卵巢综合征（PCOS）或激素替代疗法。

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Kiyoshi Ito
The Tohoku journal of experimental medicine, 212(1), 1-12 (2007-04-28)
Hormone replacement therapy (HRT) has become available over the past few decades, but the risk of breast cancer with HRT remains controversial. The Women's Health Initiative Study has recently demonstrated that women receiving estrogen plus progestin (HRT) have an increased
Susannah J Stanway et al.
The oncologist, 12(4), 370-374 (2007-05-02)
Inhibitors of steroid sulfatase are being developed as a novel therapy for hormone-dependent breast cancer in postmenopausal women. Data suggest that steroid sulfatase (STS) activity is much higher than aromatase activity in breast tumors and high levels of STS mRNA
Emma M Ferguson et al.
Water research, 47(4), 1604-1615 (2013-01-12)
Estuaries are often the final repositories for aquatic pollutants but how estuarine hydrology influences the availability of marine- and freshwater-derived pollutants is not well understood, particularly for micro-pollutants such as endocrine disrupting chemicals. To address this knowledge gap, this study
Ghada N Farhat et al.
Journal of the National Cancer Institute, 105(19), 1496-1503 (2013-09-18)
Although high endogenous sex hormone levels and estrogen plus progestin (E+P) therapy are associated with increased breast cancer risk, it is unknown whether pretreatment levels of sex hormones modify E+P effect on breast cancer. We conducted a nested case-control study
Xavier Remesar et al.
Medicinal research reviews, 32(6), 1263-1291 (2011-02-03)
Oleoyl-estrone (OE) is a powerful slimming agent that is also present in plasma and adipose tissue, where it is synthesized. It acts through the formation of a derivative W. OE effects (and W levels) are proportional to the dose. OE
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持